Italfarmaco Announces Topline Data from Phase 2 Trial with Givinostat in Patients with Becker Muscular Dystrophy
Retrieved on:
Saturday, June 26, 2021
Research, Hospitals, Genetics, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Muscular dystrophy, Branches of biology, Health, Medicine, Becker muscular dystrophy, Dystrophin, Givinostat, Dystrophy, Duchenne muscular dystrophy, Duchenne, BMD, Becker Muscular Dystrophy, Givinostat, Italfarmaco Group, BECKER MUSCULAR DYSTROPHY, GIVINOSTAT, ITALFARMACO GROUP
Italfarmaco Group announced today topline data from its proof-of-concept Phase 2 trial with Givinostat, the companys proprietary histone deacetylase (HDAC) inhibitor, in 51 adult males with Becker Muscular Dystrophy (BMD).
Key Points:
- Italfarmaco Group announced today topline data from its proof-of-concept Phase 2 trial with Givinostat, the companys proprietary histone deacetylase (HDAC) inhibitor, in 51 adult males with Becker Muscular Dystrophy (BMD).
- The topline data was presented by Paolo Bettica on June 26, 2021, at the virtual Parent Project Muscular Dystrophy (PPMD) Annual Conference .
- The Phase 2 trial investigating Givinostat in BMD patients was a randomized, double-blind, placebo-controlled study (ClinicalTrials.gov: NCT03238235 ).
- Italfarmaco is also investigating the effect of Givinostat treatment in patients with Duchenne Muscular Dystrophy (DMD) in a Phase 3 trial (ClinicalTrials.gov: NCT02851797 ).